In today’s rapidly evolving healthcare landscape, the need for clinical trial diversity and inclusivity has become a regulatory imperative. However, traditional recruitment methods often fall short in reaching underrepresented populations, leading to a lack of diversity in clinical research studies. This webinar aims to explore how technology can be harnessed to overcome barriers to clinical trial participation and create more inclusive clinical trials.
Join this webinar as the featured speakers delve into the potential of technology to revolutionize the recruitment and retention process today and in the future, ensuring that clinical trials are representative of the diverse patient populations they aim to serve. The expert panel of industry leaders will share their insights, experiences and success stories in leveraging technology to help drive clinical trial health equity.
This webinar highlights the transformative power of technology in clinical trials, enabling accurate study requirements, diverse applications and optimized protocols for patient populations. It emphasizes the patient-centric approach, reducing burdens on participants and staff. Telemedicine and innovative trial designs overcome geographical challenges, enhancing patient engagement. Decentralized solutions foster inclusivity, bringing trials to patients’ homes. Ethical considerations are explored, and the latest FDA guidance on decentralized trials and patient diversity plans are covered, empowering attendees to confidently navigate the regulatory landscape.
Register now to learn how clinical trial diversity and inclusivity can be improved through the use of telemedicine decentralized solutions and other technologies.
Rose Blackburne, MD, MBA, VP and Global Head of General Medicine & Women’s Health, PPD, a part of Thermo Fisher Scientific
Dr. Rose Blackburne, MD, MBA is the Vice President and Global Head of General Medicine & Women’s Health at PPD, a part of Thermo Fisher Scientific. In her role, she has strategic input and oversight for a portfolio of pharmaceutical and medical device product development opportunities across therapeutic areas including Women’s Health, Nephrology, GI, Dermatology and Urology.
Dr. Blackburne is a globally recognized leader in medical product development and has been instrumental in numerous approvals for pharmaceuticals, vaccines, medical devices and diagnostic tests. She is a thought leader in Health Equity and Diversity in Clinical Research. Since 2016, Dr. Blackburne has served on the FDA Patient Engagement Advisory Committee (PEAC) part of FDA’s Patient Focused Drug Development initiatives, appointed by the FDA Commissioner to provide advice on issues relating to the regulation of medical devices and their use by patients and to develop agency guidance and policies. Dr. Blackburne serves as the primary representative for the Health of Women/Pediatrics and Vulnerable Populations segment for PEAC.
Dr. Blackburne has over 18 years of Clinical Research & Development experience and has held numerous CRO Global leadership positions across therapeutic areas Ph I-IV programs. She has a passion for Health Equity and Women’s Health policies and leads numerous initiatives focused on improving the inclusion of underrepresented populations in clinical trials, this expertise is evidenced by her numerous publications focused on diversity in clinical trials, health equity and women’s health.
Dr. Blackburne received her medical degree at the Morehouse School of Medicine in Atlanta, Georgia and completed an Obstetrics and Gynecology residency at Columbia University in New York. She holds a Master of Business Administration from the Darden Graduate School of Business at the University of Virginia and has studied Health Policy and Health Care Delivery at Harvard University John F. Kennedy School of Government, and her BA at the University of Virginia in Charlottesville, Virginia.
Jennifer Urwongse, DCT Strategy and Innovation Director, PPD, a part of Thermo Fisher Scientific
Jennifer Urwongse has been a DCT SME since 2015, advising on patient-centric strategies to accelerate patient recruitment and increase patient engagement and retention. She provides expertise with standard and novel decentralized solutions in Phase I-IV clinical trials. She has over 15 years of industry experience in life science, healthcare, data and technology and evaluates new innovative DCT solutions/capabilities that can support clinical programs.
Julie Hockett, Feasibility Strategist, PPD, a part of Thermo Fisher Scientific
Julie Hockett is a Feasibility Strategist focused on Hematology/Oncology Feasibility Strategy at PPD. As a member of multiple cross-functional Diversity & Inclusivity in Clinical Trials teams, Julie helps lead the implementation of technology and strategic data analyses to guide thoughtful and targeted feasibility and recruitment for diverse clinical trials. Julie has a background in portfolio strategy and business development in the pharmaceutical industry, with experience at GlaxoSmithKline, Dynavax and Connetics.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Industry: Employees of Biopharma and Biotech companies involved in site and patient recruitment for clinical research and/or diversity in clinical trial initiatives
- Clinical Research Sites: Investigators and site directors of clinical research sites exploring options to reduce patient burden and access issues for clinical trial participation
- Health Care Providers: Clinicians involved in the care of clinical research patients, including those in underserved communities
- Patient Advocacy Groups: Staff members bridging the gap between the community and the clinical research ecosystems to develop patient and caregiver-centric trials
- Community-based Organizations: Local community organizations who are looking for ways to close the gap and remove barriers to access for underrepresented populations in clinical research
What You Will Learn
Register for this webinar to gain insights into:
- Technology solutions to forecast study requirements, accounting for diversity data
- Role of telemedicine and remote monitoring in enabling participation
- How applying new innovative trial designs, like virtual and mobile sites, can broaden patient access
- How decentralized solutions, such as wearables/sensors, home healthcare services, pharmacy networks and micro-sampling technology are improving accessibility
- Best practices, potential pitfalls and ethical considerations
- New FDA guidance around decentralized clinical trials (DCT) and patient diversity plans
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, enables customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, its capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services. Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, PPD clinical research serves pharma, biotech, medical device and government organizations with custom-tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, the business applies cutting-edge technologies, therapeutic expertise and a firm commitment to quality to help customers deliver life-changing therapies.